See “New York’s Life Science Disruptors” on March 12: Here’s the Agenda

Join us March 12 for New York's Life Science Disruptors

We’re coming down the home stretch towards our latest Big Apple biotech bash.

In just a few weeks, on March 12, Xconomy will bring the local biotech community together for “New York’s Life Science Disruptors” at the Alexandria Center for Life Science at East River Science Park. It’s a candid event; you’ll hear the behind-the-scenes stories of some of the key figures who are trying to mold New York biotech. The full agenda is here.

Acorda Therapeutics (NASDAQ: [[ticker:ACOR]]) CEO Ron Cohen has come aboard to moderate one of our chats. Here are the others you’ll see:

George Yancopoulos: Scientific founder and chief scientific officer of Tarrytown, NY-based Regeneron Pharmaceuticals (NASDAQ: [[ticker:REGN]]). Yancopoulos is a principal inventor of Regeneron’s three FDA-approved drugs, and helped launch the Regeneron Genetics Center, which aims to sequence DNA from some 100,000 volunteers.

Robert Darnell: President and CEO of the New York Genome Center, a collaborative effort between 12 of the region’s big research institutions.

Thong Le: CEO of Accelerator Corp., which invests in early-stage biotechs and just opened a New York branch last year.

Misti Ushio: Managing director of New York venture firm Harris & Harris Group, and boardmember of Accelerator-NYC.

Sam Waksal: Chairman and Founder of New York-based Kadmon, and the former president and CEO of ImClone Systems. He’ll share some opening remarks.

Meg Tirrell: Biotechnology and pharmaceuticals reporter on CNBC, who, like Cohen, will join us as a chat moderator.

The festivities kick off at 5 p.m. with a networking reception before we get the show going at 6. You can grab your tickets here. See you all at the Alexandria Center in a few weeks.

Author: Ben Fidler

Ben is former Xconomy Deputy Editor, Biotechnology. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.